文献速递胸部肿瘤

早期非小细胞肺癌:生物学精准时代的风险适应性范式

Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision.
PubMed 文献 · CA Cancer J Clin · 2026-01-01

综述指出,低剂量CT筛查普及、磨玻璃影频现及从不吸烟者发病率上升,使早期可治愈肺癌占比增加,围手术期免疫与靶向治疗、液体活检等进展同步推进;但磨玻璃影管理、TNM分期难反映生物学异质性及创新可及性不均仍是障碍。作者提出以人工智能分析与多组学刻画驱动的风险适应性管理范式,对高危者升级、低危者安全降级治疗。

要点

  • 早期可治愈肺癌的检出增加,诊疗重心前移
  • 围手术期免疫与靶向治疗、液体活检等无创监测已融入精准管理
  • TNM分期无法反映早期肿瘤生物学异质性,磨玻璃影管理仍不确定

核心结论

  • 作者提出向风险适应性管理范式转变,以人工智能驱动分析和多组学刻画,按每位患者的生物学风险量身调整治疗强度。
  • 该策略对高风险个体适当升级治疗,对低风险个体允许安全降级治疗。
  • 需以这种整体、面向全生命周期的策略,为早期非小细胞肺癌患者提供公平且持久的治愈。

研究设计与样本

  • 本文为CA Cancer J Clin发表的综述,围绕早期非小细胞肺癌的诊断与治疗进展及挑战进行论述。
  • 文中未报告系统检索范围与样本量。

主要发现

  • 低剂量CT筛查广泛采用、磨玻璃影频繁检出及从不吸烟者发病率上升,使诊断重心转向更早期、潜在可治愈的疾病。
  • 治疗进展包括保留肺实质的手术技术、数字导航增强的微创平台,以及围手术期免疫治疗与靶向药物的变革性整合。
  • 液体活检等无创监测手段已成为指导精准管理的有力工具。
  • 磨玻璃影管理仍存在不确定性,基于解剖的TNM分期无法反映早期肿瘤的生物学异质性,全球创新可及性差异尚未解决。

临床怎么用

  • 临床应关注早期非小细胞肺癌的生物学风险分层,而非仅依赖解剖学TNM分期。
  • 在高危患者中考虑适当升级治疗,在低危患者中探索安全降级治疗。
  • 可将液体活检等无创监测纳入精准管理路径,并重视磨玻璃影的规范随访与决策。

局限性

  • 为综述性论述,未提供系统检索策略与定量证据汇总。
  • 风险适应性范式依赖人工智能与多组学,文中未报告其验证数据与实施细节。
  • 全球创新可及性差异被列为尚未解决的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low-dose computed tomography screening, the frequent detection of ground-glass opacities, and a rising incidence among never-smokers, the diagnostic center of gravity has shifted toward earlier, potentially curable disease. This shift has been accompanied by equally important therapeutic advances, including parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the transformative integration of perioperative immunotherapy and targeted agents. Concurrently, noninvasive monitoring approaches, such as liquid biopsy, have emerged as powerful tools to guide precision management. Despite this progress, substantial barriers to achieving a universal cure persist. Clinicians continue to face uncertainty in the management of ground-glass opacities, the anatomy-based TNM staging system fails to capture the biologic heterogeneity of early tumors, and global disparities in access to innovation remain unresolved. To address these challenges, the authors propose a shift toward a risk-adaptive management paradigm that harnesses artificial intelligence-driven analytics and multi-omics profiling to tailor treatment intensity according to each patient's biologic risk. Such an approach would enable appropriate escalation for high-risk individuals while permitting safe de-escalation for those at low risk. This holistic, lifespan-oriented strategy must be embraced to deliver equitable and durable cures for patients with early stage nonsmall cell lung cancer.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Zhang C, Gu X, Wang P, et al. Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision. CA Cancer J Clin. 2026. PMID: 42713910. doi:10.3322/caac.70100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。